Addition of lomustine for bevacizumab-refractory recurrent glioblastoma

Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma

(2014) Benedikt Wiestler et al.   JOURNAL OF NEURO-ONCOLOGY

Tumor-associated edema in brain cancer patients: pathogenesis and management

(2013) Patrick Roth et al.   Expert Review of Anticancer Therapy

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

(2013) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients

(2012) D A Reardon et al.   BRITISH JOURNAL OF CANCER

Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs

(2012) Astrid A.M. Van der Veldt et al.   CANCER CELL

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

(2012) Annika Malmström et al.   LANCET ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

Standards of care for treatment of recurrent glioblastoma—are we there yet?

(2012) Michael Weller et al.   NEURO-ONCOLOGY

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

(2011) David A. Reardon et al.   CANCER

Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients

(2011) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

(2010) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

The paradoxical effect of bevacizumab in the therapy of malignant gliomas

(2010) E. M. Thompson et al.   NEUROLOGY

Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme

(2009) Joost JC Verhoeff et al.   BMC CANCER

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

(2009) Eudocia C. Quant et al.   NEURO-ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization

(2008) A. Claes et al.   MOLECULAR CANCER THERAPEUTICS